LATEST NEWS

INMETRO’s temporary procedures facing the new Coronavirus

Date: 04/07/2020

Updated on July 2nd 2020: INMETRO published, on the 30th of June, Ordinance nº 225 which extended the terms and temporary procedures for Conformity Assessments, due to the international public health emergency resulting from the new Coronavirus. The Ordinance extends the possibility of remote audits until December 31st 2020, as well as explains the terms for companies that are going or went through, maintenance or recertifications processes during the pandemic. 

INMETRO published, on the 27th of March, Ordinance nº 111, regarding extraordinary and temporary procedures for Conformity Assessments, due to the international public health emergency resulting from the new Coronavirus.

The Ordinance establishes alternative conditions for Product Certification Bodies (CBs) to carry out Conformity Assessment activities in manufacturing plants located in countries affected by the coronavirus epidemic (COVID-19), including Brazil.

The Ordinance is only applicable for processes initiated between January 1st 2020 and June 30th  2020. For maintenance or recertifications processes, the regulation is effective only if the maintenance/expiration date of the certificate or registration is within the informed period.

For maintenance and recertification processes, the CB shall perform a risk analysis based on the records of the latest internal audits, top management´s critical analysis and complaints handling, as well as the history of non-conformities in testing. After the analysis, the CB may take the decision to postpone the maintenance or recertification audit.

In the event of the postponement, the Audit must necessarily be carried out within a maximum period of 6 (six) months, counting from the date on which the decision is registered by the CB. Alternatively, based on the risk analysis and considering the existence of adequate conditions, the CB may decide to perform a remote audit.

In the case of remote auditing, the initial, maintenance or recertification audit activity may be performed, at the CB’s discretion, dismissing the need for in house audit or scheduling a subsequent in house audit to confirm the certification. If the risk analysis does not support the audit’s postponement or if the operating conditions of the factory do not support the performance of remote auditing, the certificate must be suspended.

Regarding testing and test reports, Ordinance 111 gives the possibility for tests to be performed by the manufacturer in 1st or 3rd party laboratories accredited in Brazil or abroad, within the scope of the ILAC Mutual Recognition Arrangement (ILAC MRA), regardless of the lab acceptance criteria provided in the medical device specific Conformity Assessment Requirements.

Regardless of the extraordinary conditions, technical requirements provided for in the regulations published by INMETRO must continue to be complied with by manufacturers.

Follow us on social media to get an update on the top news regarding the Brazilian regulatory system.

DOMO Salute Team

MORE NEWS

07/18/2024
  From June 24 to 28, ANVISA participated in the MDSAP Forum and Regulatory Authority Council (RAC) meeting in Essen, Germany. The event gathered representatives from 27 countries, including regulatory authorities, MDSAP auditing organizations, and industry representatives, with notable attendance from Brazilian associations ABIMED and [...]
07/02/2024
  In force since January 2022, RDC 591/2021, which provides for the Unique Device Identification (UDI) system, was amended by ANVISA just days before the deadline for attributing and affixing UDI to risk class IV devices. The amendment was published in RDC 884/2024 on June 1, 2024, and is already in force. According to ANVISA,... Leia [...]
04/12/2024
Marking a significant advancement in regulatory reliance mechanisms, the National Health Surveillance Agency (ANVISA) published Normative Instruction (IN) 290/2024, on April 8, 2024. This normative introduces an optimized procedure for evaluating and deciding on registration petitions for medical devices previously regulated in recognized [...]
03/22/2024
Important Regulatory Update for Manufacturers under MDSAP in Brazil Today, ANVISA has announced a significant regulatory development with the publication of Resolution RDC 850/2024. This regulation brings forth a crucial amendment concerning the validity period of the Brazilian Good Manufacturing Practices (BGMP) Certificate for manufacturers [...]
01/05/2024
Collegiate Board Resolution (RDC) 837/2023, published by ANVISA on December 15th, 2023, brings updates to the rules regarding clinical investigations with medical devices performed in Brazil. Effective immediately from the publication, this resolution aligns Brazilian practices with international standards, providing clearer guidelines for [...]
12/13/2023
On 11 of December 2023, ANVISA published Collegiate Board Resolution – RDC 830/2023, addressing risk classification, registration procedures, as well as labeling requirements and instructions for use of in vitro diagnostic medical devices (IVDs) in Brazil. The new RDC, effective from June 1, 2024, is a comprehensive revision that consolidates [...]
11/28/2023
Public Consultation No. 1.208 will be open to receive contributions until December 9th. In the dynamic landscape of medical device regulations in Brazil, obtaining the Brazilian Good Manufacturing Practices (BGMP) certification is a mandatory request for manufacturers of Class III and Class IV devices seeking Registro. In a recent move towards [...]
03/01/2023
  Starting today – March 1st 2023 – the new Resolution RDC nº 751/2022  comes into force. The Resolution provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. In order to meet the new requirements and procedures, ANVISA has already [...]
09/22/2022
The Collegiate Board Resolution – RDC 751/2022 was published on the 21st of September 2022, which provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. The new RDC consolidates the risk classification and regularization regimes for all risk [...]